Ashland’s Kentucky plant is first US excipient facility to receive EXCiPACT certification

Calvert City facility marks first step in Ashland’s global pharmaceutical excipient certification initiative

Ashland's facility in Calvert City, Kentucky, has earned EXCiPACT certification for Good Manufacturing Practice (GMP). Its scope covers the manufacturing, testing and packaging of polyvinylpyrrolidone (PVP) and polyvinylpolypyrrolidone (PVPP) used as pharmaceutical excipients. According to the certifying body, EXCiPACT, this is the first US excipient facility to receive certification.

Ashland, which supplies both cellulosic and polyvinylpyrrolidone polymers to the pharmaceutical industry, along with dedicated technical expertise and support, has established a goal of having all of its global pharmaceutical excipient facilities certified by 2017.

'This achievement reflects Ashland’s commitment to providing high-quality products and services to our customers,' said Annie Tannhauser, vice president global product regulatory and quality, Ashland. 'As an industry leader, we are always challenging ourselves to be the best in the products we produce and the quality approach we use to do so.'

'The transparency and global reach of this certification programme will further patient safety through consistent, global quality standards,' added Deneen Law, global pharmaceutical marketing and innovation director, Ashland.

Companies